Cutaneous drug reactions induced by glycopeptides;Toxidermies induites par les glycopeptides

Medecine et Maladies Infectieuses

Volumn 37, Issue 5, 2007, Pages 270-274

  Prey, S ^a   Sparsa, A ^a   Boumediene, A ^a   Bonnetblanc, J M ^a   Weinbreck, P ^a   Denes, E ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Drug eruption; Teicoplanin; Vancomycin

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; GLYCOPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANAPHYLAXIS; ARTICLE; CROSS REACTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ERYTHEMA; ERYTHRODERMA; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PAPULAR RASH; PRICK TEST; PURPURA; SKIN DISEASE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; VASCULITIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EDEMA; PATHOLOGY; SKIN;

ANTI-BACTERIAL AGENTS; EDEMA; ERYTHEMA; GLYCOPEPTIDES; HUMANS; SKIN;

EID: 34248561196     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2007.03.005     Document Type: Article

References (53)

1. Polk R.E. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J. Infect. Dis. 157 (1988) 502-507
2. Soupramanien S. Red man syndrome. Crit. Care 7 (2003) 119-120
3. Wilson A.P.R. Comparative safety of teicoplanin and vancomycin. Int. J. Antimicrob. Agents 10 (1998) 143-152
4. Bergeron L. Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function. Ann. Pharmacother. 28 (1994) 581-584
5. Killian A.D. Red man syndrome after oral vancomycin. Ann. Intern. Med. 115 (1991) 410-411
6. Healy D.P. Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions. Antimicrob. Agents Chemother. 34 (1990) 550-554
7. Wallace M. Red-man syndrome: incidence, etiology, and prophylaxis. J. Infect. Dis. 164 (1991) 1180-1185
8. Sahai J. Influence of antihistamine pre-treatment on vancomycin-induced red-man syndrome. J. Infect. Dis. 160 (1989) 876-881
9. Sahai J. Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome". Antimicrob. Agents Chemother. 34 (1990) 765-769
10. Dubettier S. Red man syndrome with teicoplanin. Rev. Infect. Dis. 13 (1991) 770
11. Khurana C. Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin. Postgrad. Med. J. 75 (1999) 41-43
12. Knudsen J.D. IgE-mediated reaction to vancomycin and teicoplanin after treatment with vancomycin. Scand. J. Infect. Dis. 24 (1992) 395-396
13. Grek V. Allergic cross-reaction of teicoplanin and vancomycin. J. Antimicrob. Chemother. 28 (1991) 476-477
14. Anne S. Vancomycin anaphylaxis and successful desensitization. Ann. Allergy 73 (1994) 375-377
15. Rocha J.L. Uncommon vancomycin-induced side effects. Braz. J. Infect. Dis. 6 (2002) 196-200
16. Geraci F.E. Vancomycin. Mayo Clin. Proc. 58 (1983) 88-91
17. Schlemmer B. Teicoplanin for patients allergic to vancomycin. N. Engl. J. Med. 318 (1988) 1127-1128
18. McElrath M.J. Allergic cross-reactivity of teicoplanin and vancomycin. Lancet 1 (1986) 47
19. De Vries E. A four-year-old child with teicoplanin allergy but no evidence of cross-reaction with vancomycin. Pediatr. Infect. Dis. J. 13 (1994) 167
20. Craycraft M.E. Probable vancomycin-associated toxic epidermal necrolysis. Pediatr Infect Dis J 13 (1994) 167
21. Alexander I.I. Vancomycin-induced Stevens-Johnson syndrome. Allergy Asthma Proc. 17 (1996) 75-78
22. Vidal C. Toxic epidermal necrolysis due to vancomycin. Ann. Allergy 68 (1992) 345-347
23. Laurencin C.T. Stevens-Johnson-type reaction with vancomycin treatment. Ann. Pharmacother. 26 (1992) 1520-1521
24. Hsu S.I. Biopsy-proved acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin. Pharmacotherapy 21 (2001) 1233-1239
25. Kuechle M.K. Drug induced linear IgA bullous dermatosis : report of six cases and review of the literature. J. Am. Acad. Dermatol. 30 (1994) 187-192
26. Wiadrowski T.P. Drug-induced linear IgA bullous disease following antibiotics. Australas. J. Dermatol. 42 (2001) 196-199
27. Klein P.A. Drug-induced linear IgA bullous dermatosis after vancomycin discontinuance in a patient with renal insufficiency. J. Am. Acad. Dermatol. 42 (2000) 316-323
28. Neughebauer B.I. Bullous skin disease: an unusual allergic reaction to vancomycin. Am. J. Med. Sci. 323 (2002) 273-278
29. Joshi S. A successful challenge in a patient with vancomycin-induced linear IgA dermatosis. Ann. Allergy Asthma Immunol. 93 (2004) 101-103
30. Waldman M.A. Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Clin. Exp. Dermatol. 29 (2004) 633-636
31. Dellavalle R.P. Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. J. Am. Acad. Dermatol. 48 5 Suppl. (2003) S56-S57
32. Armstrong A.W. Vancomycin-induced linear IgA disease manifesting as bullous erythema multiforme. J. Cutan. Pathol. 31 (2004) 393-397
33. Ki Seung D. Vancomycin. Korean J. Dermatol. 40 (2002) 1132-1135
34. Marshall C. Glycopeptide-induced vasculitis - Cross-reactivity between vancomycin and teicoplanin. J. Infect. 37 (1998) 82-83
35. Michail S. Henoch-Schoenlein purpura and acute interstitial nephritis after intravenous vancomycin administration in a patient with a staphylococcal infection. Scand. J. Rheumatol. 27 (1998) 233-235
36. Markman M. Vancomycin-induced vasculitis. South. Med. J. 79 (1986) 382-383
37. Zenon G.J. Vancomycin-induced thrombocytopenia. Arch. Intern. Med. 151 (1991) 995-996
38. Peel R.K. A case of immune thrombocytopenic purpura from intraperitoneal vancomycin use. Perit. Dial. Int. 23 (2003) 506-508
39. Mizon P. Thrombocytopenia induced by vancomycin-dependent platelet antibody. Vox Sang. 73 (1997) 49-51
40. Garner S.F. Teicoplanin-dependent antibodies: detection and characterization. Br. J. Haematol. 129 (2005) 279-281
41. Veldman R.G. Teicoplanin-induced thrombocytopenia. Nephron 73 (1996) 721-722
42. Sidoroff A. Acute generalized exanthematous pustulosis (AGEP) : a clinical reaction pattern. J. Cutan. Pathol. 28 (2001) 113-119
43. Chu C.Y. Acute generalized exanthematous pustulosis due to teicoplanin. Dermatology 202 (2001) 141-142
44. Roujeau J.C. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch. Dermatol. 127 (1991) 1333-1338
45. Joshi P.P. Fixed drug eruption with vancomycin. Ann. Pharmacother. 36 (2002) 1104
46. Gilmore E.S. Extensive fixed drug eruption secondary to vancomycin. Pediatr. Dermatol. 21 (2004) 600-602
47. Forrence E.A. Vancomycin associated exfoliative dermatitis. Pharmacotherapy 24 (1990) 369-371
48. Gutfeld M.B. Vancomycin associated exfoliative dermatitis during continuous ambulatory peritoneal dialysis. Drug Intell. Clin. Pharm. 22 (1988) 881-882
49. Neal D. Exfoliative reaction to vancomycin. BMJ 296 (1988) 13
50. Paul C. Érythrodermie induite par la teicoplanine. Ann. Dermatol. Venereol. 119 (1992) 667-669
51. Davenport A. Allergic cross-reactivity to teicoplanin and vancomycin. Nephron 63 (1993) 482
52. Bégaud B. Imputabilité des effets inattendus ou toxiques des médicaments. Therapie 40 (1985) 111-118
53. Roujeau J.C. Nécrolyse épidermique : mécanisme de l'apoptose des kératinocytes. Med. Sci. (Paris) 22 (2006) 188-191